1. Home
  2. Companies
  3. RHY
  4. Material Events

Rhythm Biosciences (ASX:RHY) — Material Events

ASX:RHY · 14 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 12 articles Notable 1 article Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
12
Rhythm Biosciences Secures Key Accreditation for ColoSTAT® Test, Paving Way for Market LaunchMedium
Rhythm Biosciences’ ColoSTAT® test gains NATA accreditation, advancing commercial launch and reimbursement prospects
9 Mar 2026 ·Regulatory Update ·85
Rhythm Biosciences Hits First ColoSTAT Sale and NHS Evaluation MilestoneMedium
Rhythm Biosciences achieves first ColoSTAT® sale, advances NHS evaluation, and expands geneType™ partnerships in Q3 FY26
30 Apr 2026 ·Appendix 4C and Business Update ·85
Rhythm Biosciences Strengthens Balance Sheet and Expands ColoSTAT® Commercial FootprintMedium
Rhythm Biosciences strengthens balance sheet and expands ColoSTAT® commercial rollout in Q4 FY26
30 July 2026 ·Quarterly Activities Report and Appendix 4C ·85
Rhythm Biosciences Launches geneType™ in Southeast Asia via Digistain DealMedium
Rhythm Biosciences Signs Distribution Deal with Digistain to Launch geneType™ in Southeast Asia
4 Mar 2026 ·Distribution Agreement ·80
Rhythm Biosciences Accelerates ColoSTAT® Launch with $3.75m Capital BoostMedium
Rhythm Biosciences advances ColoSTAT® commercialisation, secures $3.75m capital raise, and reports strong Genetype growth in Q1 FY26
29 Oct 2025 ·Appendix 4C Quarterly Cash Flow and Business Update ·80
Rhythm Biosciences Launches ColoSTAT® Blood Test Commercialisation After ISO UpgradeMedium
Rhythm Biosciences launches commercialisation of ColoSTAT® colorectal cancer blood test after ISO accreditation update
12 Dec 2025 ·Commercialisation Announcement ·80
Rhythm Biosciences Enrolls First Physician in ColoSTAT Access ProgramMedium
Rhythm Biosciences launches ColoSTAT Access Program with first physician enrolment, advancing commercial deployment
11 Feb 2026 ·Commercial Deployment Announcement ·80
Rhythm Biosciences Reports $5.93m Loss Amid First Commercial Sales and NHS EvaluationMedium
Rhythm Biosciences reports $5.93m loss, achieves first commercial sales, and advances ColoSTAT® and geneType™ platforms
27 Aug 2026 ·Annual Financial Report ·75
Rhythm Biosciences Validates ColoSTAT® Test Pathway, Poised for Rapid Scale-UpMedium
Rhythm Biosciences completes first commercial ColoSTAT® test sale, ready to scale
11 Mar 2026 ·ASX Announcement ·75
Rhythm Biosciences Locks in Multi-Year Manufacturing Deal for ColoSTAT® KitsMedium
Rhythm Biosciences Secures Multi-Year Manufacturing Deal with Quansys for ColoSTAT® Kits
3 Feb 2026 ·Commercial Manufacturing Agreement ·75
Rhythm Biosciences Navigates $2.26M Loss Amid ColoSTAT Commercial BreakthroughMedium
Rhythm Biosciences reports $2.26M half-year loss amid ColoSTAT commercial launch and geneType expansion
18 Feb 2026 ·Appendix 4D Half-Year Report ·75
Rhythm Biosciences Expands ColoSTAT® Reach with 4Cyte Pathology DealMedium
Rhythm Biosciences partners with 4Cyte Pathology to expand ColoSTAT® colorectal cancer test distribution across eastern Australia
17 Feb 2026 ·Commercial Agreement Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.